67 results about "Mouse Intestine" patented technology

The invention discloses application of phlebopus portentosus polysaccharide in preparation of medicines or foods for regulating intestinal flora, reducing blood fat and reducing weight, and belongs to the technical field of biological medicines. The research on the effect of the phlebopus portentosus polysaccharide on obese model mice finds that the polysaccharide can reduce the occurrence of cardiovascular diseases such as atherosclerosis and the like, and has the effect of protecting the liver from being damaged. In addition, the liver injury state of the obese mouse is obviously relieved, the content of total short-chain fatty acid (SCFAs) of the obese mouse is increased, the species diversity of intestinal flora of the mouse is adjusted to a certain extent, and the colony composition is optimized.

The invention discloses a construction method and application of a probiotic engineering bacterium EcNpAm targeting animal intestinal tracts and improving inflammation. According to the present invention, the heterologous expression of the immunomodulatory protein Amuc1100 is successfully achieved through the gene engineering technology by using the Escherichia coli Niss1917 (EcN) as the host and using the anaerobic inducible plasmid pnirBMisL as the expression vector, and the novel engineering bacterium EcNpAm suitable for the animal intestinal anaerobic environment is constructed; furthermore, the expression efficiency of the target protein is represented by fusion expression of green fluorescent protein (GFP). The engineering bacterium is applied to prevention and treatment of animal intestinal inflammation, and successfully realizes targeted delivery of therapeutic protein to intestinal tracts of mice. Experiments show that EcNpAm can effectively relieve typical symptoms such as weight loss, colon shortening, pathological injury, colitis and the like of mice induced by dextran sodium sulfate (DSS) and protect integrity and functions of an intestinal barrier structure.

The invention discloses a composition for synergistically regulating intestinal flora and application thereof. The composition comprises the following components in parts by weight: 10-80 parts of a cordyceps militaris extract, 2-40 parts of quercetin, 5-50 parts of prebiotics and 5-80 parts of nucleotide. The compositions provided by the invention supplement each other, have a synergistic effect, are compounded according to a scientific proportion, can improve the diversity of intestinal microorganisms of mice and the abundance of species, and can significantly improve intestinal inflammation symptoms in a mouse colitis model.

The invention belongs to the technical field of biology, and discloses a preparation method of an intestinal plexus patch, which comprises the following steps: killing an intestinal tract donor, fixing intestinal tissue segments of duodenum, jejunum, ileum or colon by using paraformaldehyde, and dehydrating to obtain dehydrated intestinal tissue segments; washing the dehydrated intestinal tissue section and removing mesentery, fat and Pari's lymph nodes attached to the jejunum, cutting an intestinal mass of about 4-6mm perpendicular to the intestinal tissue section, flatly laying the intestinal mass on a glass slide, dropwise adding a PBS (Phosphate Buffer Solution) of Triton X-100, fixing the intestinal mass by using a smooth surface of a pair of tweezers, stripping muscle tissues along the annular muscle direction, and drying the intestinal mass in a drying oven. The intestinal slices with intermuscular nerve plexus are obtained; finally, the intestinal piece with the intermuscular nerve plexus is cleaned, then fluorescent staining and piece sealing are conducted, and the mouse intestinal nerve plexus patch is obtained. The preparation method of the mouse intestinal nerve plexus patch has the advantages of being convenient, rapid and the like.

The application discloses application of Clostridium herbivorans in improving litter performance of mammals, and a probiotic preparation containing Clostridium herbivorans, wherein the viable bacterial count of Clostridium herbivorans in the probiotic preparation is 10 6 ~10 10 million / mL. After the Clostridium herbivorans colonizes in the intestinal tract of mice, the number of litters and the number of live litters of the mice can be improved.

The invention relates to the technical field of biological medicines, in particular to application of extracellular vesicles of Ackermann muciniphila in preparation of trichina control products. Experiments prove that by supplementing the AKK bacterium extracellular vesicles, the intestinal flora of a mouse can be remarkably improved, the immune balance of a host is regulated, and the pathological change of the intestinal tract of the mouse can be improved. Experimental results show that the AKK bacterium extracellular vesicles have a certain protection effect on trichina infected mice and have the advantages of being efficient, safe, easy to produce on a large scale and the like, and a brand new technical solution is provided for prevention and treatment of trichinosis.

A mouse intestinal pathological section embedding box is provided with an anti-collision block for fixing a Swiss roll, two non-woven fabric sheets, and a punching assembly for punching the Swiss roll. When in operation, the Swiss roll is fixed by the anti-collision block and the two non-woven fabric sheets, so that gaps are not easily generated in the formed wax block, and the subsequent sectioning and staining are more favorable, and the intestinal canal is not damaged. The method for making pathological sections comprises the following steps: separating the matched tool box from the embedding box body, punching the anti-collision block with a suitable punch, cleaning and rolling the mouse intestinal canal fixed by formalin into a Swiss roll; inserting the Swiss roll into the hole by using external force and flattening the protruding part of the intestinal canal tissue with a blade, placing the two layers of non-woven fabric to clamp the anti-collision block into the embedding box for tissue dehydration, peeling off the Swiss roll from the anti-collision block after dehydration and making a wax block; freezing and re-solidifying after heating and melting the paraffin, and then sectioning. The method can improve the overall morphological quality of pathological sections, and there is no phenomenon of structural loss.

The present application relates to the field of biotechnology, and particularly relates to a composition, a culture medium and application thereof in intestinal organoid culture. The present application first applies glucosamine hydrochloride to the culture of intestinal organoids, which can effectively promote organ proliferation and differentiation, and significantly increase the number of organ formation. On this basis, the present application constructs a three-dimensional culture system for postpartum neonatal, childhood and adult stages, and realizes the precise construction of mouse intestinal organoids at different development stages by combining dynamic regulation of extracellular matrix and optimization of growth factor combinations, thereby providing an in-vitro model covering multiple time sequences for intestinal development mechanism research and disease modeling.

The invention relates to a method for screening and identifying metabolites and florae with a human immune regulation effect, which comprises the following steps: (1) establishing immune system humanized mice with multiple intestinal types, and analyzing the change of the florae, the metabolites and the immune system through intestinal flora sequencing, serum metabolome sequencing, flow cytometry and transcriptome sequencing; (2) determining the correlation and sequence between flora related metabolites and the change of the immune system through bioinformatics analysis; and (3) confirming the regulation and control relationship between the candidate metabolites and the immune subgroups in the step (2) through biological experiments. By means of the screening method, the chemical small molecule metabolites for regulating and controlling the human immune cells in the normal physiological state can be screened on a large scale, and the chemical small molecule metabolites can be developed into immunotherapy drugs or used as cell therapy drug culture system components. The screened propionic acid can promote cytotoxicity of T cells and CAR-T and secretion of related cytokines in the aspect of function regulation of the T cells, and the metabolite 2-hydroxybutyric acid is highly positively correlated with the Treg cells and can promote generation and functions of the Treg cells.

The invention discloses an application of gelatinized intestinal epithelial cells in preparation of drugs for treating inflammatory bowel disease, the gelatinized intestinal epithelial cells take mouse intestinal epithelial cells as cores, poly (ethylene glycol) diacrylate, a photoinitiator and poly-L-lysine permeate into the cells through low-temperature freeze thawing, and an intracellular porous hydrogel skeleton is formed through ultraviolet crosslinking. The gelated intestinal epithelial cell has a strong cfDNA and inflammatory factor removal function, has good biocompatibility, has no direct or indirect toxic effect on a human body, has no potential toxicity, and can be used for treating inflammatory bowel diseases.

The mouse intestine roll specimen preparation device comprises a box body, a box cover, a sliding plate and an insertion column, the top face of the box body is open, and the box cover is connected to the opening of the top face of the box body in an inserted mode; the sliding plate is located on the inner bottom face of the box body, the side face of the sliding plate is slidably connected with the inner side wall of the box body, and the sliding plate slides in the vertical direction. The upper surface of the sliding plate is symmetrically provided with two rows of jacks, each row of jacks comprises three jacks, the lower ends of the insertion columns are provided with insertion blocks, and the insertion blocks are connected with the holes in a pluggable mode. According to the mouse intestine dehydration device, after the mouse intestine is completely dehydrated, the sliding plate and the insertion columns are moved upwards to be completely away from formalin solution, and the insertion columns are pulled out of the insertion holes, so that the mouse intestine can be conveniently taken down from the insertion columns, and subsequent sample manufacturing is facilitated; the mouse intestine is in a specific shape, and after the mouse intestine is soaked in a formalin solution and dehydrated, the mouse intestine has a plurality of straight sections, so that the later processing and manufacturing of specimens are facilitated.

The present application relates to a kind of crude extract of magnolia flower and its preparation method and application, the preparation method of the crude extract of magnolia flower includes: fresh magnolia flower is sequentially dried, pulverized, screened and then obtains magnolia flower powder;The required quality of magnolia flower powder is weighed, under the conditions of extraction temperature 40-80 ℃, extraction pressure 10-30 Mpa, entrainer concentration 40%-80%, entrainer flow rate 0.5-2.5 ml / min, supercritical CO2 extraction is carried out for 1-3 hours to obtain the crude extract of magnolia flower;The crude extract of magnolia flower is rotary evaporated to dryness, and the crude extract of magnolia flower is obtained.The present application uses magnolia flower as raw material, uses supercritical CO2 extraction technology to prepare the crude extract of magnolia flower, uses excessive antibiotics to induce intestinal flora disorder of mouse, establishes weak mouse model of spleen deficiency, and by using different concentrations of the crude extract of magnolia flower to the mouse is treated by gavage, find that the crude extract of magnolia flower can balance its intestinal flora, adjust the weak state of mouse of spleen deficiency, and improve immunity.

The invention discloses bifidobacterium breve for regulating metabolism of vitamin A in intestinal flora and application of the bifidobacterium breve, and belongs to the field of microorganisms. According to the bifidobacterium breve CCFM1489 disclosed by the invention, vitamin A can be subjected to external metabolism to generate retinoic acid; corneal injury and conjunctival goblet cell injury of mice with xerophthalmia are relieved; the RA level in serum of the dry-eye mouse is improved; the levels of IL-6, IL-17 and TNF-alpha in serum of the mouse with the dry eye syndrome are reduced, the intestinal flora of the mouse with the dry eye syndrome is regulated, and the abundance of beneficial bacteria is increased. Therefore, the bifidobacterium breve CCFM1489 has a huge application prospect in preparation of products for preventing and / or relieving xerophthalmia.

The invention relates to the field of biological medicine, in particular to application of a quinic acid derivative. The quinic acid derivative comprises one or two of 3-O-p-coumaroyl quinic acid and 4-O-p-coumaroyl quinic acid, and the quinic acid derivative comprises one or two of 3-O-p-coumaroyl quinic acid and 4-O- The applications include treatment and / or prevention of depression. The quinic acid derivatives 3-O-p-coumaroyl quinic acid and 4-O-p-coumaroyl quinic acid can be used for improving the behavioristics of depressive mice; the compound can significantly increase dopamine and noradrenaline in the brain of a depressive mouse, reduce the levels of inflammatory factors IL-6 and TNF-alpha in the brain of the depressive mouse, increase the intestinal microbial diversity of the depressive mouse and significantly increase the BDNF level in the brain of the depressive mouse, and can be used as a drug for treating and / or preventing depression.

The invention belongs to the technical field of medicine preparation, discloses a preparation method of a composite microbial preparation, focuses on a specific co-disease group of'depression-constipation-sleep disorder 'for the first time, provides a single-preparation comprehensive solution for comprehensively adjusting'intestine-brain axis' through multi-strain synergy, and fills the market blank. Constipation indexes are as follows: the intestinal tract propulsion rate of mice is increased by 50%, and the discharge time of first black feces is shortened by 30%. The depression index is as follows: in a forced swimming experiment, the immobile time is reduced by 40%, and the sweet water preference is obviously increased. Sleep indexes are as follows: the total sleep time is prolonged by 25%, and the sleep latency period is shortened by 20%. Biochemical indexes are as follows: the level of inflammatory factor IL-6 in serum is reduced by 60%, and the content of 5-HT and GABA in colon tissue is remarkably increased.

The invention provides an application of exemestane or a derivative thereof in preparation of a medicine for preventing radioactive intestinal injury, and also provides a pharmaceutical composition for preventing radioactive intestinal injury, which consists of exemestane or a derivative thereof and pharmaceutically acceptable auxiliary materials. According to the invention, exemestane is screened and locked at high throughput from 3067 compound libraries approved by FDA for the first time. A radioactive intestinal injury mouse model verifies that 6.25 mg / kg exemestane is given for intragastric therapy 2 hours before the whole body is irradiated by 8 Gy, and the survival rate of the mouse can be remarkably increased. HE histology shows that the integrity of intestinal crypt-villus structures of mice in an exemestane administration group is recovered, the empty degree of marrow cavities is relieved, and spleen injury is relieved. The results prove that exemestane can protect intestinal tracts, hematopoietic organs and immune organs at the same time at the whole animal level, and the exemestane is a rare multi-organ integrated protection small molecule compound so far. The invention provides a new basis for exemestane or the derivative thereof to prevent radioactive intestinal injury.

The invention belongs to the technical field of molecular biology, and discloses application of DDX24 in maintaining the homeostasis of an intestinal vascular barrier. According to the present invention, the low expression of the intestinal microvascular endothelial DDX24 in the inflammatory bowel disease (IBD) is firstly found so as to construct the adult endothelial cell specific DDX24 induced knockout mouse model, the homeostasis of the intestinal vascular barrier (GVB) of the mouse is imbalanced, and the mouse suffers from spontaneous enteritis, such that the intestinal microvascular endothelial cell DDX24 is the important molecule for maintaining the intestinal homeostasis; and mechanism research finds that the intestinal microvascular endothelial cell DDX24 inhibits cell senescence to protect the GVB steady state. The research discloses an important mechanism of DDX24 for protecting GVB homeostasis by inhibiting intestinal microvascular endothelial cell senescence for the first time, and provides a strategy and basis for clinical diagnosis and treatment of IBD vascular barrier.

The invention relates to application of taurine in treatment of neonatal necrotizing enterocolitis. Experiments prove that taurine can improve intestinal inflammation of NEC mice and promote intestinal epithelial cell proliferation. The participation of taurine in the regulation and control of NEC inflammation is possibly related to a TLR4 / NF-kappa B signal. Molecular docking data shows that taurine interferes with TLR4 / MD2 protein interaction, and then TLR4 downstream inflammation signal activation is inhibited. NEC inflammation is relieved by inhibiting a TLR4 / NF-kappa B signal, and repair after NEC intestinal epithelium injury is promoted. The application of taurine in neonatal necrotizing enterocolitis is explored from animal and molecular levels, and a theoretical basis is provided for prevention and treatment of neonatal necrotizing enterocolitis.

The invention belongs to the field of health food, and particularly relates to a dendrobium officinale fermentation liquor composition with an anti-inflammatory effect and a preparation method thereof.The composition is prepared from 30-40 parts of dendrobium officinale fermentation liquor, 15-25 parts of cyclocarya paliurus juice, 10-20 parts of kiwi fruit juice, 8-12 parts of sugarcane juice, 3-5 parts of polydextrose, 2-4 parts of lemon juice and 0.5-1 part of mint. The invention further optimizes a process method for fermenting the dendrobium officinale. According to the dendrobium officinale fermentation liquor composition, the anti-inflammatory effect is remarkably improved, the immunocompetence in a mouse body can be adjusted, the remarkable protection effect on the intestinal tract of the mouse is achieved, and the total phenol content and the total sugar content of the dendrobium officinale fermentation liquor can be remarkably improved through the dendrobium officinale fermentation process.

The present application relates to the biomedical technology field, disclose a kind of dry syndrome intestinal damage mouse model construction method and its application.The construction method includes: (1) preparation contains Freund's complete adjuvant and 1mg / mL mouse intestinal epithelial cell antigen immunization emulsifier I and preparation contains Freund's incomplete adjuvant and 0.5mg / mL mouse intestinal epithelial cell antigen immunization emulsifier II;(2) to mouse injection the immunization emulsifier I or the immunization emulsifier II in batches, obtain the dry syndrome intestinal damage mouse model.The dry syndrome intestinal damage mouse model construction method provided by the present application only immunizes mouse by mouse intestinal epithelial cell antigen and adjuvant, obtains the mouse model that simultaneously shows dry syndrome and intestinal damage.The construction method not only has the advantages of high efficiency, fast, economic, but also is extremely easy to popularize and widely used, has good application value.

This invention discloses a *Bifidobacterium longum* strain capable of regulating intestinal flora abundance and intestinal health, and its applications, belonging to the field of microbial technology. This invention screened a *Bifidobacterium longum* strain CCFM5871, which significantly increased the relative abundance of *Rikenobacterium* spp. in the mouse intestine, promoted the growth of *Bacteroides davidii*, improved intestinal health, and increased the lifespan of nematodes. The *Bifidobacterium longum* CCFM5871 described in this invention, which significantly increases the abundance of *Rikenobacterium* and *Rikenobacterium* spp. in the intestine and promotes the growth of *Bacteroides davidii*, has broad application prospects in food and microecological preparations.

The invention relates to an application of bifidobacterium animalis subsp. Lactis BLa80 in preparation of a preparation for improving Parkinson's disease. The bifidobacterium animalis subsp. Lactis BLa80 is a strain of the bifidobacterium animalis subsp. Lactis BLa80 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.22547, and the strain of the bifidobacterium animalis subsp. Lactis BLa80 is a strain of the bifidobacterium animalis subsp. Lactis BLa80 with the preservation number of CGMCC No.22547. The brand new application of the BLa80 strain of the animal bifidobacterium subsp. Lactis is developed, namely the BLa80 strain is used for improving the Parkinson's disease, specifically, the BLa80 strain can weaken the cytotoxicity of 6-OHDA induced SH-SY5Y cells, relieve weight loss of MPTP induced subacute Parkinson's disease model mice, relieve dyskinesia of the mice and improve the Parkinson's disease. According to the present invention, the mice are subjected to the mouse striatum activation, such that the dopaminergic neuron is protected, the dopamine content in the mouse striatum is increased, the intestinal inflammation is relieved, the ratio of the thick-wall mycophylum to the bacteroides in the mouse intestinal flora is increased, the intestinal beneficial flora abundance is improved, and the intestinal flora diversity is increased;

This invention relates to the field of pharmaceutical technology, specifically to the application of porcine deoxycholic acid (HDCA) in the preparation of a drug for alleviating colitis. The dosage of HDCA is 50-200 mg / kg body weight / day. The colitis referred to is DSS-induced colitis, inflammatory bowel disease, or ulcerative colitis. Administration is by gavage. The drug alleviates colitis by promoting the proliferation of intestinal stem cells and / or repairing intestinal barrier function. This method can reverse the decrease in food intake and body weight in mice under DSS, reduce their disease activity index, and alleviate the problem of DSS-induced colon shortening in mice; simultaneously, HDCA also promotes the proliferation of intestinal stem cells, repairs intestinal permeability, and alleviates DSS-induced damage to the intestinal mucosal barrier function in mice. It can inhibit the expression of intestinal inflammation-related genes in mice, alleviating inflammatory complications. It helps to reshape the intestinal flora of mice, especially promoting Akkermansia colonization and alleviating intestinal barrier damage.

The application provides application of Elaeagnus conferta polysaccharide in preparation of a medicine for treating intestinal barrier related diseases, and relates to the technical field of natural medicine chemistry. The intestinal protection effect of the Elaeagnus conferta polysaccharide on a dextran sodium sulfate induced intestinal injury model of mice is investigated, and the research result shows that the Elaeagnus conferta polysaccharide can treat clinical symptoms such as diarrhea, enteritis and weight loss caused by intestinal barrier injury, significantly reduces disease scores, inhibits colonic tissue goblet cell necrosis, promotes secretion of mucin, increases expression of tight junction proteins, and enhances intestinal mucosal barrier function. As a widely planted fruit and a fruit loved by the public, the Elaeagnus conferta has the advantages of high safety and easy acquisition. It is expected to become an effective active ingredient source for resisting intestinal injury diseases, and has a broad market development prospect.

This invention provides the application of *Pleurotus oosporum* polysaccharide in the preparation of drugs and health foods that regulate intestinal barrier function or protect against intestinal damage-related diseases. Its protective effect against a mouse model of intestinal damage induced by sodium dextran sulfate was investigated. Results showed that *Pleurotus oosporum* polysaccharide significantly improved symptoms such as weight loss, loose stools, and colonic atrophy caused by intestinal damage in mice, reduced the disease activity index, inhibited colonic epithelial destruction, inflammatory cell infiltration, and goblet cell necrosis, and enhanced intestinal mucosal barrier function. As a fungus, *Pleurotus oosporum* has high safety and is a potential source of active ingredients against intestinal damage, showing promising development prospects in intestinal barrier protection.

The invention provides an extraction and separation method of lycium barbarum polysaccharide and application of the lycium barbarum polysaccharide in preparation of an intestinal flora regulating product, and belongs to the technical field of natural plant polysaccharide. The lycium barbarum polysaccharide LBP1 and the lycium barbarum polysaccharide LBP2 prepared by the invention can obviously improve the intestinal flora structure of an immunosuppressive mouse under a high dosage, the immunosuppressive mouse treated by the lycium barbarum polysaccharide LBP1 or the lycium barbarum polysaccharide LBP2 is similar to a normal mouse in OTU number, the flora structure is also close to the level of the normal mouse, the lycium barbarum polysaccharide LBP1 and the lycium barbarum polysaccharide LBP2 have a good effect on maintaining the diversity of intestinal flora, and the lycium barbarum polysaccharide LBP1 and the lycium barbarum polysaccharide LBP2 have a good application prospect. Therefore, the lycium barbarum polysaccharide LBP1 and the lycium barbarum polysaccharide LBP2 provided by the invention can obviously improve mouse intestinal flora disorder caused by CTX under a specific dosage.

The invention provides an application of LAMP2 in diagnosis and treatment of necrotizing enterocolitis. Research finds that the expression level of the LAMP2 protein in necrotizing enterocolitis patients is remarkably reduced for the first time, and the LAMP2 protein can be used as a specific marker for assisting diagnosis of the necrotizing enterocolitis patients and has relatively high detection accuracy. Furthermore, the expression of the LAMP2A protein in NEC model mouse intestinal epithelial cells is remarkably reduced, and meanwhile, the expression of the LAMP2A protein in an HIEC6 inflammation model is also remarkably reduced. After the LAMP2A protein expression level of NEC model mice is up-regulated, inflammation and intestinal tissue damage caused by NEC can be effectively relieved, the tissue structure tends to be normal, the Nadler score is obviously reduced, and the plasma IL-1beta level is obviously reduced. Therefore, the reagent for promoting the expression level of the LAMP2A protein can be used for preparing the medicine for treating necrotizing enterocolitis.

The invention provides an application of ixozolamide or a derivative thereof in preparation of a medicine for preventing radioactive intestinal injury, and also provides a pharmaceutical composition for preventing radioactive intestinal injury, which is composed of ixozolamide or a derivative thereof and pharmaceutically acceptable auxiliary materials. According to the invention, high-throughput screening and locking of ethozolamide are carried out from 3067 compound libraries approved by FDA for the first time. A radioactive intestinal injury mouse model verifies that 25 or 50 mg / kg of ethofenzolamide is used for intragastric therapy 2 hours before the whole body is irradiated by 8 Gy, and the survival rate of 30 days can be remarkably increased. HE histology shows that the integrity of intestinal crypt-villus structures of mice in an exozolamide administration group is recovered, the empty degree of marrow cavities is relieved, and spleen injury is relieved. The results prove that the esozolamide can protect intestinal tracts, hematopoietic organs and immune organs at the same time at the whole animal level, and the esozolamide is a rare multi-organ integrated protection small-molecule compound so far. The invention provides a new basis for the protection of radioactive intestinal injury by the ixozolamide or the derivative thereof.

The application provides an application of exemestane or a derivative thereof in preparation of a medicine for protecting against radiation-induced intestinal injury, and further provides a medicine composition for protecting against radiation-induced intestinal injury, which is composed of exemestane or a derivative thereof and pharmaceutically acceptable adjuvants. The application first screens and locks the exemestane from a high-throughput screening of 3067 compounds approved by FDA. Through a mouse model of radiation-induced intestinal injury, it is verified that the survival rate of mice can be significantly improved by intragastrically treating the mice with 6.25 mg / kg of exemestane 2 hours before whole body 8 Gy irradiation. HE histology shows that the intestinal crypt-villus structure integrity of the mice in the exemestane administration group is recovered, the bone marrow cavity emptiness degree is reduced, and the spleen injury is reduced. The above results prove that the exemestane can protect the intestine, hematopoietic and immune organs at the whole animal level, and is a rare small molecule compound for protecting multiple organs. The application provides a new basis for exemestane or a derivative thereof for protecting against radiation-induced intestinal injury.

The invention belongs to the technical field of formula food for special medical purposes, and particularly discloses animal and plant peptide-containing formula food suitable for inflammatory bowel diseases and a preparation method of the animal and plant peptide-containing formula food. The nutritional food has the advantages of good flowability and solubility, good nutrient uniformity, high quality, no residue feeling, easy absorption, high safety and the like, and meets the requirements of patients with inflammatory enteritis on nutritional food. The composition has the following specific effects: (1) the composition has a recovery effect on intestinal tracts of mice with enteritis; and (2) the low-FODMAP dietary fiber has the effect of improving intestinal inflammation of enteritis patients. (3) the lactose content is extremely low, so that the milk powder is suitable for people with lactose intolerance to eat, and (4) the milk powder has the effects of regulating the pH value of intestinal tracts of mice and proliferating probiotics.